IOTA Diagnostic receives CDSCO approval for cervical cancer screening test

M-Strip is an indigenously built novel advancement for cervical cancer screening

IOTA Diagnostic, Ahmedabad-based medtech startup in bio-sampling solutions, has announced a significant milestone with the recent approval of its groundbreaking M-Strip device by the Central Drugs Standard Control Organization (CDSCO) in India.

The M-Strip is an indigenously built novel advancement for cervical cancer screening which empowers women to mark themselves safe by self-sampling in the comforts and privacy of their homes. This revolutionary method for cervical cancer screening using menstrual blood, follows a study conceptualised by Dr Somesh Chandra, the principal investigator, which was carried out in collaboration with Sterling Accuris, a leading diagnostic chain in northwest India. 

Vaibhav Shitole, the founder of IOTA Diagnostic, alongside Dr Somesh Chandra, a renowned oncologist from Ahmedabad and Rajiv Sharma from Sterling Accuris are the inventors and Co-Filers of the patent for the M-Strip device. Recently, the company was granted a design patent for the device by the Indian Patent Office.

The M-Strip, an innovative technology based on a dried blood cell matrix, signifies a monumental leap forward in bio-sampling solutions for women health. By harnessing the power of menstrual fluid, the M-Strip empowers women with unparalleled privacy and addresses entrenched societal taboos, revolutionising the easy detection of Human Papillomavirus (HPV) and other infectious diseases in the comfort at their home. 

This milestone achievement follows the successful launch of IOTA Diagnostic's central patented technology, the IOTA BioSampler, at Global Bio-India 2023. The device received further recognition when it was unveiled by the Chief Minister of Gujarat, Bhupendrabhai Patel, at the pre-Vibrant Biotechnology Summit in Gujarat. 

Published on : 29th May, 2024